Keywords
How to Cite
Abstract
Gastrointestinal stromal tumors (GISTs) are uncommon mesenchymal tumors in cats that originate from interstitial cells of Cajal (ICC). ICCs are mesenchymal cells found within the muscle layers of the alimentary tract that facilitate communication between the autonomic nervous system and smooth muscles. In this case, lapatinib, a tyrosine kinase inhibitor (TKI) that targets EGFR1 and HER2, was used as part of precision therapy for metastatic GIST in an 8-year-old, 2.7 kg, spayed, female mixed-breed cat, guided by the high expression of these receptors in the tumor. The treatment resulted in partial remission of liver metastases, with a progression-free survival of 171 days and an overall survival of 192 days after starting lapatinib. Lapatinib was well tolerated, with minimal adverse gastrointestinal effects. These findings highlight the potential role of molecular profiling in guiding targeted therapy for feline GISTs and suggest that lapatinib may be a viable treatment option for EGFR1/HER2-positive tumors. Further studies are needed to evaluate the efficacy and safety of TKIs in veterinary oncology, as well as their impact on long-term survival and quality of life in feline patients with GISTs.
References
Abd El-Aziz, A. M., Ibrahim, E. A., Abd-Elmoghny, A., El-Bassiouny, M., Laban, Z. M., Saad El-Din, S. A., & Shohdy, Y. (2017). Prognostic value of Her2/neu expression in gastrointestinal stromal tumors: Immunohistochemical study. Cancer Growth and Metastasis, 10, 1179064417690543. http://doi.org/10.1177/1179064417690543.
Anjos, D. S., Civa, P. A. S., Werner, J., Vicente, I. S. T., & Fonseca-Alves, C. E. (2024). Immunohistochemistry of different tyrosine kinase receptors in canine solid tumors—Part I: Proposal of a receptor panel to predict therapies. International Journal of Molecular Sciences, 25(15), 8438. http://doi.org/10.3390/ijms25158438. PMid:39126006
Berger, E. P., Johannes, C. M., Jergens, A. E., Allenspach, K., Powers, B. E., Du, Y., Mochel, J. P., Fox, L. E., & Musser, M. L. (2018). Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs. Journal of Veterinary Internal Medicine, 32(6), 2045-2053. http://doi.org/10.1111/jvim.15335. PMid:30307656.
Cabanos, H. F., & Hata, A. N. (2021). Emerging insights into targeted therapy-tolerant persister cells in cancer. Cancers (Basel), 13(11), 2666. http://doi.org/10.3390/cancers13112666. PMid:34071428.
Civa, P. A. S., Fonseca-Alves, C. E., & Dos Anjos, D. S. (2024). Long-term survival of a cat with a metastatic gastrointestinal stromal tumor. Journal of Feline Medicine and Surgery Open Reports, 10(1), 20551169241247442. http://doi.org/10.1177/20551169241247442.
Değirmenci, N. S., Uslu, M., Kırbaş, O. K., Şahin, F., & Önay Uçar, E. (2022). Lapatinib loaded exosomes as a drug delivery system in breast cancer. Journal of Drug Delivery Science and Technology, 75, 103584. http://doi.org/10.1016/j.jddst.2022.103584.
Elliott, J. W., Swinbourne, F., Parry, A. T., & Baines, L. (2017). Successful treatment of a metastatic, gastrointestinal stromal tumour in a dog with toceranib phosphate (Palladia). The Journal of Small Animal Practice, 58(7), 416-418. http://doi.org/10.1111/jsap.12657. PMid:28199021.
Fujii, Y., Iwasaki, R., Ikeda, S., Chimura, S., Goto, M., Yoshizaki, K., Sakai, H., Ito, N., & Mori, T. (2022). Gastrointestinal stromal tumour lacking mutations in the KIT and PDGFRA genes in a cat. The Journal of Small Animal Practice, 63(3), 239-243. http://doi.org/10.1111/jsap.13416. PMid:34409605.
LeBlanc, A. K., Atherton, M., Bentley, R. T., Boudreau, C. E., Burton, J., Curran, K. M., Dow, S., Giuffrida, M. A., Kellihan, H. B., Mason, N. J., Oblak, M., Selmic, L. E., Selting, K. A., Singh, A., Tjostheim, S., Vail, D. M., Weishaar, K. M., Berger, E. P., Rossmeisl, J. H., & Mazcko, C. (2021). Veterinary Cooperative Oncology Group: Common Terminology Criteria for Adverse Events (VCOG-CTCAE v2) following investigational therapy in dogs and cats. Veterinary and Comparative Oncology, 19(2), 311-352. http://doi.org/10.1111/vco.12677. PMid:33427378.
Maeda, S., Sakai, K., Kaji, K., Iio, A., Nakazawa, M., Motegi, T., Yonezawa, T., & Momoi, Y. (2022). Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs. Scientific Reports, 12(1), 4. http://doi.org/10.1038/s41598-021-04229-0. PMid:35027594.
Mechahougui, H., Michael, M., & Friedlaender, A. (2023). Precision oncology in gastrointestinal stromal tumors. Current Oncology (Toronto, Ont.), 30(5), 4648-4662. http://doi.org/10.3390/curroncol30050351. PMid:37232809.
Mino-Kenudson, M. (2017). Immunohistochemistry for predictive biomarkers in non-small cell lung cancer. Translational Lung Cancer Research, 6(5), 570-587. http://doi.org/10.21037/tlcr.2017.07.06. PMid:29114473.
Nguyen, S. M., Thamm, D. H., Vail, D. M., & London, C. A. (2015). Response evaluation criteria for solid tumours in dogs (v1.0): A Veterinary Cooperative Oncology Group (VCOG) consensus document. Veterinary and Comparative Oncology, 13(3), 176-183. http://doi.org/10.1111/vco.12032. PMid:23534501.
Nishida, T., Naito, Y., Takahashi, T., Saito, T., Hisamori, S., Manaka, D., Ogawa, K., Hirota, S., & Ichikawa, H. (2024). Molecular and clinicopathological features of KIT/PDGFRA wild-type gastrointestinal stromal tumors. Cancer Science, 115(3), 894-904. PMid:38178783.
Olmsted, G. A., Farrelly, J., Post, G. S., & Smith, J. (2017). Tolerability of toceranib phosphate (Palladia) when used in conjunction with other therapies in 35 cats with feline oral squamous cell carcinoma: 2009–2013. Journal of Feline Medicine and Surgery, 19(6), 568-575. http://doi.org/10.1177/1098612X16638118. PMid:26951557.
Rammohan, A., Sathyanesan, J., Rajendran, K., Pitchaimuthu, A., Perumal, S. K., Srinivasan, U., Ramasamy, R., Palaniappan, R., & Govindan, M. (2013). A gist of gastrointestinal stromal tumors: a review. World Journal of Gastrointestinal Oncology, 5(6), 102-112. http://doi.org/10.4251/wjgo.v5.i6.102. PMid:23847717.
Schaefer, I. M., DeMatteo, R. P., & Serrano, C. (2022). The GIST of advances in treatment of advanced gastrointestinal stromal tumor. American Society of Clinical Oncology Educational Book, 42(42), 1-15. http://doi.org/10.1200/ EDBK_351231. PMid:35522913.
Shi, S. S., Wu, N., He, Y., Wei, X., Xia, Q. Y., Wang, X., Ye, S. B., Li, R., Rao, Q., & Zhou, X. J. (2017). EGFR gene mutation in gastrointestinal stromal tumours. Histopathology, 71(4), 553-561. http://doi.org/10.1111/his.13251. PMid:28485054.
Treggiari, E., Giantin, M., Ferro, S., & Romanelli, G. (2023). Canine gastrointestinal stromal tumours treated with surgery and imatinib mesylate: Three cases (2018-2020). The Journal of Small Animal Practice, 64(3), 161-167. http://doi.org/10.1111/jsap.13572. PMid:36335646.
Vander Velde, R., Yoon, N., Marusyk, V., Durmaz, A., Dhawan, A., Miroshnychenko, D., Lozano-Peral, D., Desai, B., Balynska, O., Poleszhuk, J., Kenian, L., Teng, M., Abazeed, M., Mian, O., Tan, A. C., Haura, E., Scott, J., & Marusyk, A. (2020). Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor-specific selective pressures. Nature Communications, 11(1), 2393. http://doi.org/10.1038/s41467-020-16212-w. PMid:32409712.
Wang, Q., Huang, Z. P., Zhu, Y., Fu, F., & Tian, L. (2021). Contribution of interstitial cells of Cajal to gastrointestinal stromal tumor risk. Medical Science Monitor, 27, e929575. http://doi.org/10.12659/MSM.929575. PMid:33760802.
Wu, C. E., Tzen, C. Y., Wang, S. Y., & Yeh, C. N. (2019). Clinical diagnosis of gastrointestinal stromal tumor (GIST): From the molecular genetic point of view. Cancers (Basel), 11(5), 679. http://doi.org/10.3390/cancers11050679. PMid:31100836.
Yu, T. W., Yamamoto, H., Morita, S., Fukushima, R., Elbadawy, M., Usui, T., & Sasaki, K. (2024). Comparative pharmacokinetics of tyrosine kinase inhibitor, lapatinib, in dogs and cats following single oral administration. The Journal of Veterinary Medical Science, 86(3), 317-321. http://doi.org/10.1292/jvms.23-0448. PMid:38281758.
Zhao, J., Krishnamurti, U., Zhang, C., Meisel, J., Wei, Z., Suo, A., Aneja, L., Li, Z., & Li, X. (2020). HER2 IHC staining pattern is significantly associated with tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer. Pathology, Research and Practice, 216(1), 153155. http://doi.org/10.1016/j.prp.2020.153155 PMid:32871536.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 André Gustavo Alves Holanda, Patrick Antônio Sonaglio Civa, Carlos Eduardo Fonseca-Alves, Denner Santos Dos Anjos